Thursday, April 16, 2015 2:04:31 PM
The second guidance clarifies current FDA policy on pre- and postmarket data collection. It explains situations in which postmarket data collection is appropriate for premarket approval (PMA) applications, both in EAP and non-EAP situations, and provides numerous examples.
Hell at this point in the game, I'm looking for any tiny kernel of hope from these FDA MF's!
It's just crazy how long they take to get anything done. "They" are NOT looking out for US citizens..."They" only care about coffee breaks, pension plans, holidays, vacations, employee unions, their own health benefits - paid by US tax payers, and kissing the bosses big fat arse!
damn I feel better now!
Cheers to you UK!
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM